In light of Elon Musk’s recent offer to buy Twitter, Inc. (“Twitter”) there has been a resurgence in the desire to develop decentralized social media platforms. In efforts to avoid being at the whim of a single company or individual,
Background
The food tech industry has been rapidly growing in recent years with the rise in popularity of alternative (“alt-“) animal products. Such alt-animal products typically consist of non-animal (e.g., plant-based) proteins or lab-grown meat that serve as a substitute
In the first major patent infringement lawsuit in the mRNA space, on February 28, 2022, Arbutus Biopharma Corporation (“Arbutus”) and Genevant Sciences GmbH (“Genevant”) sued Moderna, Inc. and ModernaTX, Inc. (collectively “Moderna”) in the United States District Court for the
On February 28, 2022, the Patent Trial and Appeal Board (PTAB) issued a decision in Interference No. 106,115, which granted the Broad Institute, Massachusetts Institute of Technology, and Harvard University (collectively “Broad”) priority with respect to the invention of modifying
Generative content is having a moment in the form of non-fungible tokens (NFTs) powered by blockchain platforms. Continued investment and growth in the NFT market is bringing into the mainstream legal edge cases concerning the use of digital technology to
On January 4, 2022, Judge Andrews from the United States District Court for the District of Delaware denied Sarepta Therapeutics, Inc.’s (“Sarepta”) Rule 12(b)(6) motion to dismiss a complaint for infringement of U.S. Patent No. 10,526,617 filed by Regenxbio, Inc.
In April of 2021, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market. In this post we provide a 2021 year in review update on mRNA pioneers and key players and offer additional
On June 8, 2021, the USPTO issued an Order to Show Cause to Shenzhen Huanyee Intellectual Property Co., Ltd. (“the company”) and its identified Executive Director, Yusha Zhang, “for engaging in unauthorized practice before the USPTO in trademark matters, providing
Introduction
Universities and certain colleges in the United States (US) spend billions of dollars on research and development (R&D) each year to advance knowledge across the gamut of Arts, Humanities, and Science, Technology, Engineering, and Mathematics (STEM) fields. That R&D
Google’s parent company Alphabet announced the launch of a new company this week dedicated to applying deep learning methods to drug discovery.
The new company is called Isomorphic Laboratories and will be led by Demis Hassabis, also the CEO of DeepMind,
